NASDAQ:BEAT - BioTelemetry Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$45.4450 -0.60 (-1.30 %)
(As of 06/25/2018 09:56 AM ET)
Previous Close$46.05
Today's Range$45.2250 - $46.10
52-Week Range$23.30 - $47.35
Volume11,171 shs
Average Volume327,180 shs
Market Capitalization$1.51 billion
P/E Ratio46.85
Dividend YieldN/A
BioTelemetry logoBioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified


Debt-to-Equity Ratio0.77
Current Ratio1.96
Quick Ratio1.83


Trailing P/E Ratio46.85
Forward P/E Ratio34.17
P/E Growth3.46

Sales & Book Value

Annual Sales$286.78 million
Price / Sales5.20
Cash Flow$1.8466 per share
Price / Cash24.61
Book Value$7.70 per share
Price / Book5.90


EPS (Most Recent Fiscal Year)$0.97
Net Income$-15,950,000.00
Net Margins-3.13%
Return on Equity16.63%
Return on Assets8.62%


Outstanding Shares32,790,000

The Truth About Cryptocurrencies

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) issued its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.39 EPS for the quarter, beating the Zacks' consensus estimate of $0.23 by $0.16. The medical research company had revenue of $94.50 million for the quarter, compared to analyst estimates of $91.55 million. BioTelemetry had a positive return on equity of 16.63% and a negative net margin of 3.13%. The firm's revenue for the quarter was up 69.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.16 EPS. View BioTelemetry's Earnings History.

What price target have analysts set for BEAT?

7 brokers have issued 1 year price objectives for BioTelemetry's stock. Their forecasts range from $37.00 to $54.00. On average, they expect BioTelemetry's share price to reach $45.3333 in the next twelve months. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 54)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 43)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 49)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 48)
  • Dr. Peter R. Kowey M.D., FACC, FACP, FACCP, FCP, Medical Director and Chairman of Medical Advisory Board

Has BioTelemetry been receiving favorable news coverage?

Press coverage about BEAT stock has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioTelemetry earned a news impact score of 0.17 on Accern's scale. They also gave press coverage about the medical research company an impact score of 46.29 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.99%), Dimensional Fund Advisors LP (4.28%), Hood River Capital Management LLC (3.68%), Russell Investments Group Ltd. (2.44%), Allianz Asset Management GmbH (1.45%) and Allianz Asset Management GmbH (1.45%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which major investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Cannell Capital LLC, Mckinley Capital Management LLC Delaware, Cortina Asset Management LLC, Hodges Capital Management Inc., Thompson Siegel & Walmsley LLC, Millrace Asset Group Inc. and Allianz Asset Management GmbH. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Which major investors are buying BioTelemetry stock?

BEAT stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Ancora Advisors LLC, Harvest Capital Strategies LLC, BlackRock Inc., Carillon Tower Advisers Inc., Natixis, Millennium Management LLC and Hussman Strategic Advisors Inc.. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $46.0945.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $1.51 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]

MarketBeat Community Rating for BioTelemetry (BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.